Vortrag
Study design of ESCAPE-TRD, an ongoing, long-term, comparative, randomised phase IIIb clinical trial of esketamine nasal spray in treatment resistant depression
Autor:in
Vortrag
Short- and long-term comparison of esketamine nasal spray versus quetiapine extended release in patients with treatment-resistant depression: first results from ESCAPE-TRD, a randomised, multicentre phase IIIb clinical trial
Autor:in